vs
Side-by-side financial comparison of 4D Molecular Therapeutics, Inc. (FDMT) and Third Coast Bancshares, Inc. (TCBX). Click either name above to swap in a different company.
4D Molecular Therapeutics, Inc. is the larger business by last-quarter revenue ($85.1M vs $57.7M, roughly 1.5× Third Coast Bancshares, Inc.). Third Coast Bancshares, Inc. runs the higher net margin — 28.4% vs 22.8%, a 5.6% gap on every dollar of revenue. Over the past eight quarters, 4D Molecular Therapeutics, Inc.'s revenue compounded faster (5412.6% CAGR vs 17.5%).
4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.
Third Coast Bancshares, Inc. is a regional financial holding company headquartered in the U.S. Gulf Coast region. It provides a full suite of commercial and retail banking services including deposit products, business and consumer loans, mortgage services, and wealth management solutions, serving local small and medium-sized enterprises, individual consumers, and community clients across Texas and surrounding areas.
FDMT vs TCBX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $85.1M | $57.7M |
| Net Profit | $19.4M | $16.4M |
| Gross Margin | — | — |
| Operating Margin | 17.3% | — |
| Net Margin | 22.8% | 28.4% |
| Revenue YoY | 8508900.0% | — |
| Net Profit YoY | 139.1% | 20.5% |
| EPS (diluted) | $0.43 | $0.88 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $57.7M | ||
| Q4 25 | $85.1M | $56.5M | ||
| Q3 25 | $90.0K | $54.5M | ||
| Q2 25 | $15.0K | $52.0M | ||
| Q1 25 | $14.0K | $45.9M | ||
| Q4 24 | $1.0K | $46.3M | ||
| Q3 24 | $3.0K | $42.9M | ||
| Q2 24 | $5.0K | $41.7M |
| Q1 26 | — | $16.4M | ||
| Q4 25 | $19.4M | $17.9M | ||
| Q3 25 | $-56.9M | $18.1M | ||
| Q2 25 | $-54.7M | $16.7M | ||
| Q1 25 | $-48.0M | $13.6M | ||
| Q4 24 | — | $13.7M | ||
| Q3 24 | $-43.8M | $12.8M | ||
| Q2 24 | $-35.0M | $10.8M |
| Q1 26 | — | — | ||
| Q4 25 | 17.3% | 38.1% | ||
| Q3 25 | -67983.3% | 41.9% | ||
| Q2 25 | -396373.3% | 40.5% | ||
| Q1 25 | -383007.1% | 37.8% | ||
| Q4 24 | — | 38.7% | ||
| Q3 24 | -1704400.0% | 37.9% | ||
| Q2 24 | -849120.0% | 34.1% |
| Q1 26 | — | 28.4% | ||
| Q4 25 | 22.8% | 31.7% | ||
| Q3 25 | -63195.6% | 33.1% | ||
| Q2 25 | -364386.7% | 32.2% | ||
| Q1 25 | -342657.1% | 29.6% | ||
| Q4 24 | — | 29.7% | ||
| Q3 24 | -1461433.3% | 29.8% | ||
| Q2 24 | -699060.0% | 25.9% |
| Q1 26 | — | $0.88 | ||
| Q4 25 | $0.43 | $1.02 | ||
| Q3 25 | $-1.01 | $1.03 | ||
| Q2 25 | $-0.98 | $0.96 | ||
| Q1 25 | $-0.86 | $0.78 | ||
| Q4 24 | — | $0.80 | ||
| Q3 24 | $-0.79 | $0.74 | ||
| Q2 24 | $-0.63 | $0.63 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $402.7M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $505.7M | $650.5M |
| Total Assets | $566.7M | $6.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $402.7M | $175.2M | ||
| Q3 25 | $305.1M | $116.4M | ||
| Q2 25 | $293.2M | $113.1M | ||
| Q1 25 | $321.4M | $219.0M | ||
| Q4 24 | $424.9M | $371.2M | ||
| Q3 24 | $501.9M | $258.2M | ||
| Q2 24 | $541.9M | $241.8M |
| Q1 26 | — | $650.5M | ||
| Q4 25 | $505.7M | $531.0M | ||
| Q3 25 | $369.0M | $513.8M | ||
| Q2 25 | $420.9M | $496.1M | ||
| Q1 25 | $469.7M | $479.8M | ||
| Q4 24 | $510.6M | $460.7M | ||
| Q3 24 | $552.9M | $450.5M | ||
| Q2 24 | $588.3M | $435.0M |
| Q1 26 | — | $6.6B | ||
| Q4 25 | $566.7M | $5.3B | ||
| Q3 25 | $424.0M | $5.1B | ||
| Q2 25 | $473.6M | $4.9B | ||
| Q1 25 | $515.7M | $4.9B | ||
| Q4 24 | $560.4M | $4.9B | ||
| Q3 24 | $604.0M | $4.6B | ||
| Q2 24 | $620.1M | $4.5B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.6M | — |
| Free Cash FlowOCF − Capex | $28.5M | — |
| FCF MarginFCF / Revenue | 33.5% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | 1.47× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-109.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $28.6M | $50.8M | ||
| Q3 25 | $-46.5M | $20.7M | ||
| Q2 25 | $-43.4M | $13.9M | ||
| Q1 25 | $-47.8M | $10.5M | ||
| Q4 24 | $-134.6M | $35.1M | ||
| Q3 24 | $-29.4M | $22.0M | ||
| Q2 24 | $-30.2M | $7.3M |
| Q1 26 | — | — | ||
| Q4 25 | $28.5M | — | ||
| Q3 25 | $-46.6M | — | ||
| Q2 25 | $-43.4M | — | ||
| Q1 25 | $-48.4M | — | ||
| Q4 24 | $-138.4M | $33.4M | ||
| Q3 24 | $-31.2M | — | ||
| Q2 24 | $-30.6M | — |
| Q1 26 | — | — | ||
| Q4 25 | 33.5% | — | ||
| Q3 25 | -51765.6% | — | ||
| Q2 25 | -289620.0% | — | ||
| Q1 25 | -345635.7% | — | ||
| Q4 24 | -13837100.0% | 72.1% | ||
| Q3 24 | -1038966.7% | — | ||
| Q2 24 | -611840.0% | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | — | ||
| Q3 25 | 101.1% | — | ||
| Q2 25 | 440.0% | — | ||
| Q1 25 | 4507.1% | — | ||
| Q4 24 | 378600.0% | 3.8% | ||
| Q3 24 | 59266.7% | — | ||
| Q2 24 | 6980.0% | — |
| Q1 26 | — | — | ||
| Q4 25 | 1.47× | 2.84× | ||
| Q3 25 | — | 1.15× | ||
| Q2 25 | — | 0.83× | ||
| Q1 25 | — | 0.77× | ||
| Q4 24 | — | 2.56× | ||
| Q3 24 | — | 1.72× | ||
| Q2 24 | — | 0.68× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FDMT
Segment breakdown not available.
TCBX
| Net Interest Income | $53.6M | 93% |
| Noninterest Income | $4.0M | 7% |
